REPLIGEN CORP · Exercise / conversion · Stock Option (Right to Buy)

What does this filing report?

An SEC Form 4 filing for REPLIGEN CORP records an exercise / conversion involving Stock Option (Right to Buy) on November 13, 2025. The reported quantity was 2,952. The filing date is November 14, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Derivative terms

Underlying security

Common Stock

Underlying quantity

2,952

Conversion / exercise price

33.87

Exercise date

Not reported

Expiration date

February 29, 2028

Filing footnotes & remarks

F1

$151.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.53 to $151.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2

$152.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.57 to $152.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3

$153.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.64 to $153.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4

$154.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.66 to $154.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5

$155.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.78 to $155.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6

$156.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.79 to $156.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7

$157.11 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.90 to $157.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8

14,760 of the shares underlying this option have vested. The remaining shares vest as follows: 2,952 shares on March 1, 2026, and 2,952 shares on March 1, 2027.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.